Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Head and Neck Cancer
Interventions
DRUG

Placebo

Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.

DRUG

Ketamine Topical

Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.

Trial Locations (1)

73117

OU Health Stephenson Cancer Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT06660017 - Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse | Biotech Hunter | Biotech Hunter